Novartis AG (FRA:NOT0) ROE % Adjusted to Book Value: 4.44% (As of Mar. 2026)


FRA:NOT0 Novartis AG FRA:NOT0
83 GF Score
Price €18.20
GF Value €15.09
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG ROE % Adjusted to Book Value?

Novartis AG FRA:NOT0 83 ROE % Adjusted to Book Value is 4.44% as of Mar. 2026. GuruFocus rates FRA:NOT0 with a GF Score™ of 83/100 and a GF Value™ of €15.09 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Novartis AG's ROE % for the quarter that ended in Mar. 2026 was 30.04%. Novartis AG's PB Ratio for the quarter that ended in Mar. 2026 was 6.77. Novartis AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 4.44%.

Novartis AG ROE % Adjusted to Book Value Related Terms

Novartis AG ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Novartis AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG ROE % Adjusted to Book Value Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 5.65

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.29 7.83 7.54 4.11 4.44

FRA:NOT0 vs LLY, JNJ, ABBV: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novartis AG ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Novartis AG's ROE % Adjusted to Book Value falls into.


FRA:NOT0
83GF Score
Novartis AG FRA:NOT0
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG ROE % Adjusted to Book Value Calculation

Novartis AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=29.32% / 5.19
=5.65%

Novartis AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=30.04% / 6.77
=4.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 4.44% mean?
Novartis AG (FRA:NOT0) has a ROE % Adjusted to Book Value of 4.44% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Novartis AG and its competitors.
Is Novartis AG's ROE % Adjusted to Book Value too high?
Novartis AG's current ROE % Adjusted to Book Value is 4.44%. Overall, Novartis AG has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's ROE % Adjusted to Book Value compare to LLY and JNJ?
Novartis AG's ROE % Adjusted to Book Value of 4.44% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Novartis AG and its competitors. Novartis AG's current ROE % Adjusted to Book Value is 4.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOT0) is currently considered Modestly Overvalued. The stock's GF Value™ is €15.09, compared to a current price of €18.20 — trading 20.6% above its estimated fair value. The current ROE % Adjusted to Book Value is 4.44%. Novartis AG's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Novartis AG (FRA:NOT0), the current ROE % Adjusted to Book Value is 4.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (FRA:NOT0) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €18.20 is trading 20.6% above its estimated GF Value™ of €15.09. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOT0:

  • ROE % Adjusted to Book Value: 4.44%
  • GF Value™: €15.09 vs. price of €18.20 (20.6% above fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the FRA:NOT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score

Get the complete analysis for FRA:NOT0

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.20
Price
€15.09
GF Value